Navigating Acute Myeloid Leukemia Treatment: Therapy-Related & De Novo AML with Dr. Naval Daver

In this episode of the Oncology Brothers podcast, we discussed two challenging cases focused on Acute Myeloid Leukemia (AML). We welcomed Dr. Naval Daver, a leading expert from MD Anderson Cancer Center, to discuss: therapy-related AML and de novo AML where induction chemotherapy is not an option.

Episode Highlights:
• Overview of therapy-related AML and its increasing prevalence due to advancements in solid tumor treatments.
• In-depth discussion on the prognosis and treatment options for patients with complex cytogenetics.
• Comparison of induction treatments: CPX-351 vs. the traditional 7 + 3 regimen, including survival rates and side effects.
• Insights into the use of hypomethylating agents combined with venetoclax for older patients with AML, particularly those with NPM1 mutations.
• Practical considerations for administering these treatments in both inpatient and outpatient settings.

Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode provides valuable insights into the complexities of AML management.

Follow us on social media:
•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers
•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers
•⁠  Website: https://oncbrothers.com/

Don't forget to subscribe for more discussions on treatment algorithms, conference highlights, and the latest FDA approvals!

#AcuteMyeloidLeukemia, #TherapyRelatedAML, #DeNovoAML, #TransplantIneligible, #OncologyBrothers